Dolby Laboratories logo

Dolby Laboratories

DLB | NYSE
Chart Builder DCF Calculator
$61.16
-$2.45 (-3.85%)
At close: Nov 16, 2026, 4:00 PM ET
$60.65
-$0.51 (-0.83%)
After-hours: Nov 16, 2026, 5:47 PM ET
-3.85%

No price chart data available for 1D timeframe.

Rating

Updated: Nov 16, 2026
53.9
Fundamentals Average
Market Sentiment Bullish
Moat Narrow
Sector Rank #329/817 (Top 40%)

Key Statistics

Market Data

Market Cap $5.73B
1D Range
59.28 62.95
52W Range
48.51 69.09

Valuation (TTM)

PE 26.03
PB 2.22
EV/EBITDA 13.70

Valuation (NTM)

Forward PE 14.72
Forward PEG 4.46
Price Target $85.00
Loading financial charts...

Profile

Dolby Laboratories, Inc. develops pioneering audio and visual technologies designed to enhance entertainment and communication experiences across a broad spectrum of platforms. These include cinematic...

Sector Technology
Employees 2,051
IPO Date Feb 17, 2005
Fiscal Year October - September

Latest News

Unveiling Dolby Laboratories (DLB) Q4 Outlook: Wall Street Estimates for Key Metrics

4 days ago · zacks.com

Unveiling Dolby Laboratories (DLB) Q4 Outlook: Wall Street Estimates for Key Metrics
CervoMed Announces Publication of Two Peer-Reviewed Research Articles Supporting Neflamapimod as a Potential Treatment for Dementia with Lewy Bodies (DLB)

19 days ago · globenewswire.com

CervoMed Announces Publication of Two Peer-Reviewed Research Articles Supporting Neflamapimod as a Potential Treatment for Dementia with Lewy Bodies (DLB)
Dolby Laboratories Announces Conference Call and Webcast for Q4 Fiscal 2026 Financial Results

1 month ago · prnewswire.com

Dolby Laboratories Announces Conference Call and Webcast for Q4 Fiscal 2026 Financial Results
Dolby Laboratories: Weak Growth, But The Valuation Is Too Cheap

1 month ago · seekingalpha.com

Dolby Laboratories: Weak Growth, But The Valuation Is Too Cheap
Cognition Therapeutics Schedules a Type C Meeting with FDA to Align on Endpoints for Phase 3 Trial of Zervimesine (CT1812) in DLB

2 months ago · globenewswire.com

Cognition Therapeutics Schedules a Type C Meeting with FDA to Align on Endpoints for Phase 3 Trial of Zervimesine (CT1812) in DLB

2 months ago · zacks.com

Dolby Expands Meta Partnership With Atmos and Vision Across Devices
Dolby and Meta Expand Dolby Atmos and Dolby Vision Across Meta's Ecosystem

2 months ago · gurufocus.com

Dolby and Meta Expand Dolby Atmos and Dolby Vision Across Meta's Ecosystem
Dolby Laboratories, Inc. Grants Inducement Equity Awards Under Its 2026 Inducement Stock Plan

2 months ago · prnewswire.com

Dolby Laboratories, Inc. Grants Inducement Equity Awards Under Its 2026 Inducement Stock Plan
Dolby Expands Dolby OptiView Platform with New Capabilities at IBC 2026

2 months ago · prnewswire.com

Dolby Expands Dolby OptiView Platform with New Capabilities at IBC 2026
Dolby Laboratories (DLB) is a Top-Ranked Growth Stock: Should You Buy?

3 months ago · zacks.com

Dolby Laboratories (DLB) is a Top-Ranked Growth Stock: Should You Buy?

Earnings

Next Earnings
Nov 17, 2026
EPS Est
Pro
Rev Est
Pro
Earnings Details ➞

Analyst Summary

# of Analysts
2
Consensus
Buy
Price Target
$85.00
Upside
+38.98%
Buy (2)
Hold (0)
Sell (0)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.